Annual report [Section 13 and 15(d), not S-K Item 405]

Fair Value Measurements (Tables)

v3.25.1
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Financial Instrument Measured On Recurring Basis

  

    As of December 31, 2024     Fair Value Measurements  
    Carrying     Fair     As of December 31, 2024  
    Amount     Value     Level 1     Level 2     Level 3  
Liabilities:                              
Note payable:                                        
BroadOak loan   $ 4,400     $ 4,290     $ -     $ -     $ 4,290  
    $ 4,400     $ 4,290     $ -     $ -     $ 4,290  

 

          Fair Value Measurements  
    As of December 31, 2023     As of December 31, 2023  
    Carrying
Amount
    Fair Value     Level 1     Level 2     Level 3  
Liabilities:                              
Contingent consideration:                                        
Asuragen (1)   $ 453     $ 453     $ -     $ -     $ 453  
Note payable:                                        
BroadOak loan     10,000       9,343       -       -       9,343  
    $ 10,453     $ 9,796     $ -     $ -     $ 9,796  

 

(1)(2) See Note 10, Accrued Expenses and Other Long-Term Liabilities
Schedule of Fair Value, Assets Measured On Recurring Basis, Unobservable Input Reconciliation

 

                      Adjustment  
                      to Fair Value/  
    December 31, 2023     Payments     Accretion/Interest Accrued     Mark to Market     December 31, 2024  
                               
Asuragen   $ 453     $ (487 )   $ 34     $ -     $ -  
                                         
BroadOak loans     9,343       (5,600 )     -       547       4,290  
                                         
    $ 9,796     $ (6,087 )   $ 34     $ 547     $ 4,290